Posted on July 18, 2018
NEHI has submitted the following comments in response to the Request for Information: “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.” NEHI is a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. Its mission is to advance innovations that improve health, enhance the quality of health care, and achieve greater value for the money spent. NEHI consults with its broad membership, conducts research, and publishes thought leadership to advance these objectives.
The HHS Request for Information requests comments on four objectives: increasing competition, better negotiation, creating incentives to lower list prices, and reducing patient out-of-pocket spending. NEHI's comments are addressed to the “better negotiation” objective, and specifically to the questions pertaining to value-based arrangements and price reporting, indication-based payments, and long-term financing models.
NEHI's response is relevant to the pricing of most pharmaceuticals and is especially relevant to the class of innovative and costly new therapies such as are emerging from the expedited approval pathways of the U.S. Food and Drug Administration (FDA). Although the national debate over drug pricing and drug spending encompasses many discrete issues, NEHI encourages a special focus on high-cost biopharmaceutical innovations. Reaping the fruits, and spreading the benefits, of the innovation that is occurring in biopharmaceuticals now requires equal innovation in public policy.